Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T cell replacement therapy - Kiadis Pharma

Next Previous
Drug Profile

T cell replacement therapy - Kiadis Pharma

Alternative Names: ATIR; ATIR-101; ATIR-201; ATIR101; Reviroc™; Rhitol™; T cell replacement therapy TH9402

Latest Information Update: 16 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Montreal
  • Developer Kiadis Pharma
  • Class Haematopoietic stem cells therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Follicular lymphoma; B-cell lymphoma; Bone marrow transplant rejection; Transplant rejection; Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Beta-thalassaemia; Bone marrow transplant rejection; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 16 Jan 2026 Discontinued - Phase-I/II for Beta-thalassaemia in United Kingdom (IV)
  • 16 Jan 2026 Discontinued - Phase-II for Acute myeloid leukaemia (Recurrent) in Belgium (IV)
  • 16 Jan 2026 Discontinued - Phase-II for Acute myeloid leukaemia (Recurrent) in Germany (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top